With ever-increasing health care spending and insatiable demand for new drugs, the biotechnology sector looks poised for good growth going forward.... ...

Gilead Sciences, Inc. (GILD) recently presented encouraging data on its pipeline candidate idelalisib (formerly GS-1101) from a phase II study... ...

Gilead Sciences, Inc (GILD) suffered two successive setbacks when the US Food and Drug Administration (FDA) issued complete response letters (CRLs)... ...

We expect Eli Lilly and Company (LLY) to beat earnings expectations when it reports first-quarter 2013 results before the opening bell on Apr 24,... ...

We expect Bristol-Myers Squibb Company (BMY) to report in line first-quarter 2013 results before the opening bell on Apr 25. Factors to Consider... ...

Top Coverage News